1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Wesana Health Holdings Inc.
  6. News
  7. Summary
    WESA   CA95081C1059

WESANA HEALTH HOLDINGS INC.

(WESA)
  Report
Delayed CANADIAN NATIONAL STOCK EXCHANGE  -  03:29 2022-06-24 pm EDT
0.2000 CAD    0.00%
06/08WESANA HEALTH CEO DANIEL CARCILLO TO KEYNOTE CHARLES RIVER SYMPOSIUM : Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies
AQ
05/31Wesana Announces First Quarter 2022 Financial Results
AQ
05/31Wesana Health Holdings Inc. Announces Resignation of Chad Bronstein as Executive Chairman
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Wesana Explores Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder

04/18/2022 | 06:34pm EDT

Wesana Health Holdings Inc. announced that following the completion of a successful Pre-IND meeting with the United States Food and Drug Administration, the Company is exploring the opportunity to expand its lead indication for SANA-013 to Major Depressive Disorder following the completion by the Company of a non-brokered private placement. Consistent with the positive feedback received from the FDA, Wesana is also exploring the opportunity to accelerate the development of SANA-013 by initiating a Phase 1b/2a human study for MDD in the first half of 2023. In contrast to the current development pathway for SANA-013 with TBI associated anxiety as the lead indication, currently targeting the launch of a Phase 1 study in Fourth Quarter of 2022 in a healthy human patient population, the revised development pathway would allow the Company to bypass the healthy patient population study and research an MDD affected patient population directly as part of a Phase 1b/2a study. MDD is a chronic, recurring, and debilitating mental disorder leading it to be one of the most burdensome illnesses on a global scale. Patients suffering from MDD are frequently and significantly impaired from an occupational and social function standpoint resulting in severe economic costs.


© S&P Capital IQ 2022
All news about WESANA HEALTH HOLDINGS INC.
06/08WESANA HEALTH CEO DANIEL CARCILLO TO : Re-Imagining Substance Abuse, Addiction, and Mental..
AQ
05/31Wesana Announces First Quarter 2022 Financial Results
AQ
05/31Wesana Health Holdings Inc. Announces Resignation of Chad Bronstein as Executive Chairm..
CI
05/30Wesana Health Holdings Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
05/10Wesana Health Outlines Accelerated Drug Development Pathway
AQ
05/10Wesana Health Holdings Outlines Accelerated Drug Development Pathway
CI
05/05Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its..
AQ
05/05Wesana Health Holdings Announces Review of Strategic Alternatives of its Clinics and Ot..
CI
05/02Wesana Health Reports Q4 2021 Financial Results and Provides Subsequent Period Highligh..
AQ
05/02Wesana Health Holdings Inc. Reports Earnings Results for the Full Year Ended December 3..
CI
More news
Financials (USD)
Sales 2022 1,56 M - -
Net income 2022 -21,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,31x
Yield 2022 -
Capitalization 3,14 M 3,14 M -
Capi. / Sales 2022 2,02x
Capi. / Sales 2023 1,15x
Nbr of Employees -
Free-Float 99,1%
Chart WESANA HEALTH HOLDINGS INC.
Duration : Period :
Wesana Health Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,15 $
Average target price 3,09 $
Spread / Average Target 1 896%
EPS Revisions
Managers and Directors
Daniel Carcillo Chief Executive Officer & Director
Zed Wang Chief Financial Officer & Secretary
Chad Bronstein Executive Chairman
Mark Wingertzahn Chief Scientific Officer
Mitchell Kahn Director
Sector and Competitors
1st jan.Capi. (M$)
WESANA HEALTH HOLDINGS INC.-86.01%3
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
LONZA GROUP AG-32.67%39 851
SEAGEN INC.16.00%33 010
CELLTRION, INC.-13.38%18 371